
Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

Your AI-Trained Oncology Knowledge Connection!


Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

H. Jack West, MD, takes a moment to talk about what he is finding in regard to anaplastic lymphoma kinase (ALK) rearrangements seen in approximately 4% of patients with non�small cell lung cancer, as reviewed by Shaw et al in a September 2009 issue of the Journal of Clinical Oncology.